American Century Companies Inc. Cuts Position in IDEXX Laboratories, Inc. $IDXX

American Century Companies Inc. trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.3% during the 3rd quarter, Holdings Channel reports. The fund owned 705,158 shares of the company’s stock after selling 148,003 shares during the period. American Century Companies Inc.’s holdings in IDEXX Laboratories were worth $450,518,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at about $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the third quarter valued at about $31,000. Armstrong Advisory Group Inc. raised its position in shares of IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $35,000. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 20,873 shares of company stock worth $13,408,523 in the last ninety days. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $656.73 on Friday. The business’s 50 day moving average price is $672.95 and its 200 day moving average price is $668.97. The company has a market cap of $52.29 billion, a price-to-earnings ratio of 50.25, a PEG ratio of 4.01 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the firm earned $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. UBS Group decreased their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. Barclays cut their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.